Akebia Therapeutics Inc. (NASDAQ:AKBA)‘s stock had its “buy” rating reaffirmed by investment analysts at JMP Securities in a report issued on Thursday.

The analysts wrote, “Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (NASDAQ: AKBA), Array Biopharma (NASDAQ: ARRY) and Phibro Animal Health (NASDAQ: PAHC) | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘https://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=07a193bd66&wpp_id=459641’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (NASDAQ: AKBA), Array Biopharma (NASDAQ: ARRY) and Phibro Animal Health (NASDAQ: PAHC)”

A number of other research firms have also recently commented on AKBA. Zacks Investment Research upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 19th. HC Wainwright reiterated a “buy” rating on shares of Akebia Therapeutics in a research note on Tuesday, August 23rd. Credit Suisse Group AG reiterated a “hold” rating and issued a $8.00 price objective on shares of Akebia Therapeutics in a research note on Tuesday, August 9th. Finally, Brean Capital started coverage on Akebia Therapeutics in a research note on Thursday, September 29th. They issued a “buy” rating and a $18.00 price objective on the stock. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Akebia Therapeutics has a consensus rating of “Buy” and a consensus target price of $14.43.

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Shares of Akebia Therapeutics (NASDAQ:AKBA) opened at 8.77 on Thursday. The firm’s market cap is $160.49 million. Akebia Therapeutics has a 12 month low of $7.00 and a 12 month high of $13.20. The firm’s 50-day moving average price is $8.30 and its 200-day moving average price is $8.40.

Akebia Therapeutics (NASDAQ:AKBA) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.96) EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.13. During the same period last year, the firm earned ($0.47) EPS. Analysts expect that Akebia Therapeutics will post ($3.47) earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of AKBA. Nantahala Capital Management LLC raised its position in Akebia Therapeutics by 507.8% in the first quarter. Nantahala Capital Management LLC now owns 1,347,326 shares of the biopharmaceutical company’s stock valued at $12,139,000 after buying an additional 1,125,652 shares during the period. TFS Capital LLC purchased a new position in shares of Akebia Therapeutics during the second quarter valued at about $1,296,000. Morgan Stanley raised its position in shares of Akebia Therapeutics by 52.4% in the third quarter. Morgan Stanley now owns 337,506 shares of the biopharmaceutical company’s stock valued at $3,054,000 after buying an additional 116,001 shares during the last quarter. BlackRock Fund Advisors raised its position in shares of Akebia Therapeutics by 8.2% in the second quarter. BlackRock Fund Advisors now owns 1,408,498 shares of the biopharmaceutical company’s stock valued at $10,536,000 after buying an additional 107,049 shares during the last quarter. Finally, Segantii Capital Management Ltd purchased a new position in shares of Akebia Therapeutics during the third quarter valued at about $897,000. 50.97% of the stock is currently owned by hedge funds and other institutional investors.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology.

5 Day Chart for NASDAQ:AKBA

Receive News & Stock Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related stocks with our FREE daily email newsletter.